Edinburgh-based charity the Global Alliance for Livestock Veterinary Medicines (GALVmed) has announced three drug discovery contracts in an effort to combat animal African Trypanosomosis (AAT), a disease which is estimated to cost Africa US$5billion a year.

Animal African trypanosomosis, transmitted by the tsetse fly, is a parasitic disease which affects livestock, resulting in a chronic illness which often ends in death. An estimated 50 million cattle and 70 million sheep and goats are at risk, with around 3 million cattle dying annually from the disease.

AAT causes economic losses in livestock, reducing meat and milk production and leaving animals so weak they are unable to help cultivate land. It affects over 10 million square kilometres of fertile land spread across nearly 40 countries in Africa and therefore has a huge impact on food and nutritional security and livelihoods across the continent.

The drugs that are currently used were developed in the 1950s and 60s and drug resistance is now a commonly reported problem. With few other options available, these drugs are the most important method of controlling the disease.

In May 2011 the Department for International Development (DfID) awarded GALVmed 30 month grant for £8million to facilitate the development of drugs, diagnostics and potential vaccines for the control of AAT.

The first contract was awarded to Anacor Pharmaceuticals Inc., a California based biopharmaceutical company established in 2002.

As part of a Drugs for Neglected Diseases Initiative (DNDi) supported project, Anacor and their partners discovered a series of compounds to combat the human form of AAT, Human African Trysanosomsis (HAT). A number of compounds produced under this programme have properties which could make them suitable for the treatment and prevention of animal AAT. These relevant compounds will now be screened for efficacy and safety under the GALVmed contract.

The second and third contracts have both been awarded to the College of Life Sciences at the University of Dundee, one of Europe's top-ranked universities for life science research.

Dr Kevin Read, who is Head of Drug Metabolism and Pharmokinectics at the drug Discovery Unit is leading a piece of drug discovery and development research, which aims to develop new drugs for the treatment and possible prevention of AAT in cattle, and also a diagnostic test for use in the field. This builds on the university's work on HAT and drugs that were unsuitable for human treatment are now being re-evaluated as potential drugs for cattle.

Dr Read said: "I am very excited to be working in partnership with GALVmed to apply our extensive drug discovery expertise in HAT to identify and bring forward new potential drugs for the treatment and prevention of AAT. The new project offers an exciting opportunity to reposition compounds showing great promise for the treatment of first stage HAT into AAT, thus improving food security in some of the poorest countries in sub-Saharan Africa."

Merial Animal Health has announced the launch of its new feline vaccine Purevax Rabies in the UK and Ireland.

Merial says the product offers a simple but elegant solution to rabies vaccination, without the need for adjuvant. According to the company, the non-replicative vector is processed by the cat's immune system in the same way as a live virus, triggering both a powerful cell mediated and humoral response without the need for adjuvant. However, because the vector cannot replicate effectively in mammalian cells, there is no risk of any reversion to virulence.

Merial's Veterinary Technical Manager Kevin Whelan, said: "This is a perfect complement to our existing range of advanced technology vaccines, which already offer the benefits of highly effective protection, including updated FCV strains, without the need for adjuvant. It also represents Merial's continued commitment to the development of innovative products for the animal health market".

The vaccine is licensed for use in cats from 12 weeks of age, and administration of a single injection has been shown to provide protection against disease.

Contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.

Clinicians at the Queen Mother Hospital for Animals at the Royal Veterinary College have become the first team in the UK to successfully treat acromegaly in a cat with hypophysectomy surgery.

According to the RVC, this make it the first centre in the UK, and only the fourth in the world, to offer this procedure. The patient groups that might benefit from this RVC-exclusive procedure include cats and dogs with non-functional pituitary tumors, cats and dogs with hyperadrenocorticism (Cushing's disease) and cats with acromegaly or hypersomatotropism.

The RVC says removing the pituitary gland and the associated tumour which causes acromegaly or hyperadrenocorticism is the gold standard treatment in humans suffering from these diseases since it offers the greatest chance of a complete cure for the disease.

Prior to the RVC offering surgical treatment, the only treatment options available for acromegalic cats in the UK were radiation therapy or simply treatment of the resulting diabetes mellitus. The latter can prove extremely difficult and frustrating and the former unpredictable, unreliable and/or ineffective. Even when a complete response to the radiation therapy eventually occurs, hormonal abnormalities usually persist.

Dr Stijn Niessen, leading the hypophysectomy team at the Royal Veterinary College, said: "I'm extremely proud to be able to offer this unique surgery for the first time in the UK at the RVC. As a relatively new and innovative procedure in veterinary medicine there are risks involved, as is recognised with every form of neurosurgery of this level. However, despite these risks, this surgery does offer owners a chance for the best possible result for their pet using a single procedure. Hypophysectomy therefore represents the most elegant treatment method currently available enabling complete removal of the brain tumor and normalisation of damaging excessive hormone levels that are causing hormonal diseases like acromegaly and hyperadrenocorticism.

"Especially when a pituitary tumor is diagnosed late, the alternative treatment method of radiation therapy might well take too long to take effect and devastating neurological signs might occur due to the pressure of the pituitary tumor on the surrounding brain. In such cases, hypophysectomy can make an instant difference in relieving that pressure. However, in general, we would advocate the procedure to be considered as soon as possible following diagnosis, thereby preventing the animal's body from becoming more and more negatively affected by the excessive hormone levels associated with pituitary diseases like acromegaly and hyperadrenocorticism."

Dr. Niessen, a European Veterinary Specialist in Internal Medicine with research interests in diabetes and endocrinology and world-expert in acromegaly, will be selecting the patients suitable for the new treatment, preparing them for surgery and managing the aftercare programme. The longer-term aftercare programme will include hormone replacement treatment administered through eye-drops (usually temporarily) and tablets (permanent) to manage the hormone production lost through removal of the pituitary gland.

The surgery itself will be performed by Patrick Kenny, a European and American Specialist in Veterinary Neurology and Neurosurgery.

The RVC says the surgery would not be possible without the multidisciplinary approach at the Queen Mother Hospital for Animals, which includes the Internal Medicine, Neurology and Neurosurgery, Diagnostic Imaging, Anaesthesia and Emergency and Critical Care teams as well as a team of highly qualified nurses.

To support ongoing research in this field, the Royal Veterinary College is offering free blood tests for all diabetic dogs and cats which include fructosamine evaluation and screening tests for the presence of acromegaly in cats. Cats that record high hormone levels indicative of acromegaly will qualify to undergo a free CT scan for confirmation. If acromegaly is confirmed, all possible treatment options will be discussed with the client, including the hypophysectomy procedure. To request a free blood test for a patient please visit: www.rvc.ac.uk/cic

Veterinary surgeons currently managing a cat or dog with a pituitary tumor who are considering referral of this case can also contact Dr Stijn Niessen for further information at the QMHA on 01707 666365  or at qmhreception@rvc.ac.uk

Supreme Petfoods has announced that Think Rabbit Fortnight, a campaign to help practices engage with rabbit owners, will run from Monday 21st May to Friday 1st June.

Practices can decide how much they wish to participate in the campaign and can opt to receive goodie bags, a 'Think Rabbit' manual detailing how the practice can be more rabbit-friendly, or take the 'Small Furry' Promise.

The event is being backed by RCVS Exotics Specialist, Molly Varga. She said: "I'd encourage all practices to take part in Think Rabbit Fortnight to help improve the health and welfare of the nation's rabbits."

Supreme says that practices which take part in the Think Rabbit Campaign will also have the opportunity to sign up for Level 1 of its 'Better for Bunnies, Better for Business' programme, which it says can double turnover derived from rabbits through an increase in new clients, average visit transaction spend and attendance rates of existing clients.*

Claire Hamblion, Marketing Manager at Supreme says she hopes that it will really encourage practices to focus on how they can develop protocols and routines that will remove barriers to rabbit owners seeking healthcare advice and presenting their pet for treatment.

Binky - voted Britain's Cutest Bunny - will play a starring role in the Think Rabbit campaign to attract the attention of rabbit owners who will also be asked to nominate their rabbit as a VIP (Very Important Pet). Claire said: "Our VIP won't necessarily be the most prettiest, fastest or cleverest bunny but one that has special qualities in the eyes of its owner. I hope vets and nurses will help spread the word and maybe even nominate some very important patients."

To sign up for Think Rabbit Fortnight, visit www.supremepetfoods.com/thinkrabbit, email thinkrabbit@companionconsultancy.com, or telephone 01284 761107.

*Supreme - Better for Bunnies, Better for business programme, Onswitch March 2012

Dechra has launched a two hour online CPD session on skin and ear cytology for veterinary surgeons and nurses.

The module was created in conjunction with Peter Forsythe BVM&S DVD MRCVS RCVS Specialist in Veterinary Dermatology.

Senior Brand Manager at Dechra Veterinary Products, Larry King, said: "Cytology is a key to diagnosing otitis externa, a common condition seen by vets and nurses but one which can be challenging to manage.

"Carrying out cytology will assist them in deciding on the appropriate approach to control the infection. Our online CPD module, presented through a series of videos, will explain cytology step by step from initial presentation to organism identification."

Peter Forsythe added: "It is difficult to practice good dermatology without doing cytology, which is inexpensive, quite quick to do and is a great aid in the diagnosis of skin disease. These videos cover the investigation of pyoderma, Malassezia and otitis externa, but actually this is just the tip of the iceberg and the same techniques can be used for investigation of a range of other inflammatory skin diseases."

The free of charge CPD, available at www.dechra.co.uk/academy, includes downloadable resources and a short quiz to support the module, with a certificate upon completion.

Woodley Equipment has launched ImmunoComb diganostic test kits for FIP, canine Leptospira and Ehrlichia

Woodley says the kits are easy to use and provide results within 20 minutes. No specialist laboratory equipment is required as the kits are self-contained with all the necessary reagents. The diagnostic kits determine the animal's antibody titre levels, in the case of the canine Ehrlichia as early as 7 days after infection, giving veterinary surgeons the opportunity to act more quickly in developing a prevention/treatment program.

Tests can be performed singly or up to 12 simultaneously.

For more information about ImmunoComb Diagnostic kits email sales@woodleyequipment.com or call: +44 (0) 1204 669033 Option 1. Alternatively visit http://www.woodleyequipment.com/

Bayer Animal Health has organised for prominent clinical microbiologist Dr Joseph Blondeau, from Canada's University of Saskatchewana, to tour the UK in May, giving talks to practitioners about effective antibiotic usage to prevent bacterial resistance.

Bayer's Technical Veterinary Adviser, Lucy Smith, will also be giving a talk: Maximise Treatment Success, which comes at the subject from the practical veterinary side.

Bayer Animal Health Marketing Manager, Dr Markus Edingloh said: "We are incredibly fortunate to work with such an eminent expert. Dr Blondeau is a leading authority on a new parameter that supports a dosing concept to minimise selection of bacterial resistance - the Mutant Prevention Concentration. Fortunately, he is also expert at presenting complex matters in an engaging and memorable way."

He added: "Lucy Smith will share her specific experience of Bayer's recently launched Veraflox (pradofloxacin), the first and only next generation veterinary fluoroquinolone, which has a broad spectrum of treatment which attacks Gram +, Gram - and anaerobic bacteria, in a highly efficacious way.

The evening events take place on: May 14th (Glasgow), May 15th (Derby), May 16th (Swindon) & May 17th (Surrey). Full details in the VetSurgeon Diary.

Each roadshow session is equivalent to 1.5 hours of free Continuing Professional Development (CPD).

To register to attend one of the roadshows, please email animal.health@bayer.com

Pfizer Animal Health, maker of the equine wormers Equest and Equest Pramox, has unveiled www.wormingyourhorse.info, a new website which aims to make it easier for horse owners to understand and follow the most up-to-date principles of sustainable worm control.

Based on the company's Manage, Test, Plan, Dose campaign, Pfizer says the new website is designed to take the confusion out of equine worm control with clear, logical and easy-to-understand guidance and advice.

The four main sections use diagrams and text to explain how and why it's important to manage the worm challenge on the pasture; the role of faecal worm egg counts (FWECs); how history and management play a part in planning the best worm control programme and how to choose and use the right wormer at the right time of year.

There's an interactive and educational parasite page that shows the parasites that can affect the health of your horse. There are click through buttons on parts of the horse's anatomy revealing details about the appearance of each particular parasite, their lifecycle and the symptoms they can cause. In addition there's a section on frequently asked questions which provides no-nonsense answers to some of the most commonly asked questions about worm control.

Paul Blanc, Pfizer's equine brand manager said: "In developing our new website we have listened carefully to what horse owners really want and need to know. The result is a source of plain-speaking, unbiased facts and advice, providing horse owners with the most current thinking on sustainable worm control in a format they can really identify with."

The RCVS is advising all practices that it is not currently carrying out a data-gathering exercise and that phone calls prompting the return of a survey, and requesting mobile phone numbers, are not being made on behalf of the College.

The warning comes after several practices have called the College to query 'feedback forms' - supposedly issued in relation to the Practice Standards Scheme or the payment of members' retention fees.

The practices were asked to return forms which they had not received, and also to provide mobile phone numbers, by someone who claimed to work for the 'statutory regulator' or 'the RCVS'. Contact phone numbers left by the caller were either RCVS fax numbers or numbers which looked like RCVS direct dial numbers, but were not. 

Lizzie Lockett, Head of Communications, said: "This looks like an exercise to gain mobile phone numbers which is being carried out in the College's name. We are currently investigating who might be making these calls. In the meantime, if a practice receives such a call, it would be helpful if they could take down a name and contact number and let us know." 

Ring 020 7202 0725 or email l.lockett@rcvs.org.uk to report any suspicious activity.

BSAVA Congress was invaded by Orangemen this year to promote the Vet Charity Challenge (VCC) taking place on 15^th September 2012.

Veterinary surgeons and industry colleagues are being encouraged to take part in the one day event in which teams of four will complete a series of physical tasks and puzzle-solving challenges. Teams can choose their own routes which include walking / running, cycling and kayaking stages and can make it as easy or hard as they like.

The Vet Charity Challenge is hoping to raise in excess of £20,000 for Hounds for Heroes; SPANA, and Pet Blood Bank. VCC says it will be a great PR opportunity for practices and an opportunity for team-building.

The event will take place at the Royal Agricultural College, Cirencester and all details may be found on www.vetcharitychallenge.co.uk or by phoning 01727 859259. The VCC will provide training guidelines and sponsorship forms. Places are limited so early booking is advisable. To be sure of a place, practices and business are urged to book their team of four by the deadline of Friday 29^th June 2012.

The Vet Charity Challenge is sponsored by BCF Technology, Kruuse UK Ltd and Vets2.net and is supported by the VPMA, Mojo Consultancy and JCA Media Group.

The RCVS Disciplinary Committee has dismissed charges of serious professional misconduct against a veterinary surgeon and former employee of Medivet (Watford).

Tomasz Nazimek, who qualified in Poland in 2001 before starting work in England in 2005, was alleged to have charged for the use of a blood pressure monitor during an exploratory laparotomy on a cat called Mitzi, whilst working at the Watford branch of Medivet in June 2009, when he knew, or ought to have known, it had not been used.

Despite his previous signed statements to the contrary, Mr Nazimek admitted at the outset of the hearing that no blood pressure monitor had in fact been used.

Accordingly, the Committee only had to establish whether Mr Nazimek himself had entered the fee for its use into Mitzi's records and, if so, whether this was done dishonestly.

The alleged incident came to light as a result of a covert investigation into Medivet conducted by the television production company Fulcrum TV in 2008/9, and subsequently commissioned by the BBC and broadcast in July 2010 as part of the Panorama programme 'It Shouldn't Happen at a Vets''.

Former dental nurse Alexandra Lee was employed by Fulcrum TV as an undercover reporter to work as a 'trainee veterinary nurse' at Medivet, in order to record audio and video footage of her experiences there.

The case against Mr Nazimek was based partly on a conversation overheard by Miss Lee following the operation on Mitzi, where she maintained that Guy Carter, a senior Medivet partner and veterinary surgeon, told Mr Nazimek (who was sitting at the practice computer typing up Mitzi's records) not to forget to include a fee for use of the blood pressure monitor.

However, Miss Lee's equipment had not recorded this exchange, due to a fault, and her video diary of that day's events was not put in evidence before the Committee. Miss Lee also accepted in evidence that she had not actually seen who entered the fee into the records, but had assumed it was Mr Nazimek.

Despite giving serious consideration to all of Miss Lee's evidence, the Committee found it of limited value.

The Committee considered the statements signed by Mr Nazimek, but prepared for him by the Medivet senior management in December 2009 and October 2010, which stated that he had used the monitor, consulted Mr Carter about charging for it and then added the fee himself.

The Committee also considered a third statement provided to the College (September 2011), in which Mr Nazimek recalled that Mr Carter had priced up the operation himself, but not asked for his input.

When questioned about the discrepancies in his statements, Mr Nazimek told the Committee that he had confused different operations and now knew his earlier statements to be wrong.

He indicated that he had been under pressure from his then employers to sign the statements, that his attempts to change them were ignored by Medivet's managing partners and that he was depressed and under stress at the time.

He was not told that the statements could be in relation to charges against him, or that he was entitled to legal advice when discussing them with his employers.

The Committee found Mr Nazimek's oral evidence to be persuasive, his manner open and his responses under cross-examination frank.

In the absence of satisfactory and reliable evidence to the contrary, and in view of supportive testimonials provided from his current employer and former colleagues as to his honesty and integrity, the Committee found Mr Nazimek's repeated assertion that he did not make a charge for the monitor "entirely plausible" and believed that he told the truth.

Nevertheless, the Committee emphasised that a charge for the monitor had been entered into the records when no such device had been used, which it regarded as unacceptable.

Speaking on behalf of the Committee, Chairman Professor Peter Lees said: "The Committee is not satisfied by the evidence so that it is sure that [Mr Nazimek] entered into the records for Mitzi a charge for the blood pressure monitor. [It] believes that [Mr Nazimek] told the truth when giving his evidence and the character references support his honesty.

"In these circumstances, it is not necessary to consider the charges further and the allegations against [Mr Nazimek] are dismissed."

The University of Bristol and Companion Care have launched The Great Pet Travel Survey 2012 to assess disease risks in the UK following the simplification of Pet Travel Scheme rules.

Companion Care and The University of Bristol say that there is a great deal of concern about what risks changes in the Pet Travel Scheme Rules pose to the health of the human and dog population in the UK.

Robert White-Adams MRCVS from Companion Care said: "At present there is minimal data available to answer this question as current data logging is minimal and paperwork checking at ports can be variable. We therefore have little idea of how many UK-resident dogs travel abroad, where they visit, how long they stay and what they are doing whilst abroad.

The survey will collect and analyse information about the travel patterns of UK resident dogs, in and around mainland Europe, over the last decade.

Robert added: "The data to be collated by the survey will fill the data void and enable us to provide a quantitative assessment of the disease risk, as well as gaining an understanding of owner awareness of risks face by dogs travelling in Europe.

Owners of dogs with Pet Passports are being encouraged to fill in the short questionnaire, which is available now at  http://www.greatpetsurvey.co.uk/.   All completed questionnaires will be entered into a prize draw to win £100 of Pets at Home vouchers!

The questionnaire will be live online until 30th June 2012 and all data will be analysed by the University of Bristol.

Dr Morgan said: "Without this information we have only a vague idea of the risks that the loss of border controls may pose. The answer could be that there is little additional risk or it could be that the UK dog (and human) population could face some severe disease threats. As it stands now, we just don't know enough to make an informed judgement."